Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Annexa

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

- PMLiVE

Boehringer’s Ofev approved by FDA for rare lung disease

US regulator also gives the green light to Intermune's Esbriet

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

Bristol Myers Squibb logo

BMS drops US application for ‘breakthrough’ hep C combination

Blames the 'rapidly evolving' market for asunaprevir withdrawal

- PMLiVE

Boehringer Ingelheim launches Sound Challenge app

Looks to raise awareness of rare lung disease IPF

Bristol Myers Squibb logo

First phase III data for BMS’ anti-PD1 nivolumab

Opdivo shows promise in melanoma study

- PMLiVE

PharmaVentures increases its Asia-Pacific presence

Aki von Roy will be based in Auckland, New Zealand

- PMLiVE

BMS and Pfizer to donate $1m for cardiovascular education

The money will be distributed between seven organisations

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

BMS launches hepatitis C pill Daklinza in the UK

Will be offered as a combination treatment with Gilead's Solvadi

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links